Synlogic Inc
NASDAQ:SYBX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Synlogic Inc
Cash & Cash Equivalents
Synlogic Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Synlogic Inc
NASDAQ:SYBX
|
Cash & Cash Equivalents
$14.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-17%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash & Cash Equivalents
$5.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-5%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash & Cash Equivalents
$10.6B
|
CAGR 3-Years
25%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash & Cash Equivalents
$12B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
15%
|
CAGR 10-Years
15%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash & Cash Equivalents
$6.6B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
2%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash & Cash Equivalents
$18.9B
|
CAGR 3-Years
82%
|
CAGR 5-Years
54%
|
CAGR 10-Years
37%
|
|
Synlogic Inc
Glance View
Synlogic, Inc. engages in the discovery and development of Synthetic Biotic medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 84 full-time employees. The company went IPO on 2015-09-30. The firm is focused on the discovery and development of synthetic biology therapeutics for the treatment of rare, infectious, and other diseases. Its pipeline includes its lead program in phenylketonuria (PKU). The firm's PKU program includes two development candidates, SYNB1618 and SYNB1934. SYNB1618 and SYNB1934 are orally administered, non-systemically absorbed drug candidates for PKU, which is a genetic disease caused by neurotoxic levels of the amino acid Phe. Its product pipeline includes SYNB1353 and SYNB8802. SYNB1353 is an orally administered, non-systemically absorbed live biotherapeutic drug candidate engineered to consume methionine in the gastrointestinal tract (GI) total homocysteine (tHcy) in homocystinuria (HCU) patients and allowing natural protein intake. SYNB8802 is a non-systemically absorbed drug candidate developed for the treatment of enteric hyperoxaluria.
See Also
What is Synlogic Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
14.7m
USD
Based on the financial report for Dec 31, 2025, Synlogic Inc's Cash & Cash Equivalents amounts to 14.7m USD.
What is Synlogic Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-17%
Over the last year, the Cash & Cash Equivalents growth was -22%. The average annual Cash & Cash Equivalents growth rates for Synlogic Inc have been -3% over the past three years , -15% over the past five years , and -17% over the past ten years .
